<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002650</url>
  </required_header>
  <id_info>
    <org_study_id>20131106-7</org_study_id>
    <secondary_id>20131106-7</secondary_id>
    <nct_id>NCT02002650</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin to Prevent Post-ERCP Pancreatitis</brief_title>
  <acronym>Indomethacin</acronym>
  <official_title>Routine Rectal Indomethacin Given Before Procedure Reduced Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
      30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in
      high risk patients was considered a &quot;standard&quot; method to prevent PEP. However, the risk
      factors of PEP is not fully clear. Rectal indomethacin before ERCP for all patients, not just
      for selected high-risk patients, may preventing PEP maximum. The purpose of this study is to
      determine whether routine using of rectal indomethacin is more effective than the conditional
      strategy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-ERCP Pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, serum amylase elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization prolonged at least two nights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate-to-severe Pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Moderate pancreatitis requiring hospitalization of 4-10 days. Severe pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2600</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Pre-ERCP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-ERCP rectal Indomethacin in all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-ERCP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-ERCP rectal Indomethacin in high-risk patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-ERCP rectal Indomethacin</intervention_name>
    <description>Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
    <arm_group_label>Pre-ERCP group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-operational Rectal Indomethacin</intervention_name>
    <description>Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.</description>
    <arm_group_label>Post-ERCP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing diagnostic or therapeutic ERCP.

        Exclusion Criteria:

          -  Unwillingness or inability to consent for the study;

          -  Age &lt; 18 years old;

          -  Intrauterine pregnancy;

          -  Breastfeeding mother;

          -  Standard contraindications to ERCP;

          -  Allergy to NSAIDs;

          -  Received NSAIDs in prior 7 days;

          -  Renal failure (Cr &gt;1.4mg/dl=120umol/l);

          -  Active or recurrent (within 4 weeks) gastrointestinal hemorrhage;

          -  Acute pancreatitis within 72 hours;

          -  Known pancreatic head mass;

          -  Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy
             without anticipated pancreatogram;

          -  ERCP for biliary stent removal or exchange without anticipated pancreatogram;

          -  Known active cardiovascular or cerebrovascular disease.

          -  Presence of coagulopathy before the procedure or received anticoagulation therapy
             within three days before the procedure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanglin Pan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Xijing Hospital of Digestive Diseases.The Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of NingXia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No. 451 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urumqi General Hospital of Lanzhou Military Region</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2012 Dec;76(6):1152-9. doi: 10.1016/j.gie.2012.08.021.</citation>
    <PMID>23164513</PMID>
  </results_reference>
  <results_reference>
    <citation>Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103.</citation>
    <PMID>22494121</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <results_first_submitted>April 17, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2016</results_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Yanglin Pan</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <keyword>Indomethacin, pancreatitis, ERCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From Dec 15, 2013 to Sep 21, 2015, 5325 consecutive patients undergoing ERCP in six centers in China were considered for the study.</recruitment_details>
      <pre_assignment_details>After screening, 2725 patients were excluded: 193 did not meet inclusion criteria, 2304 met exclusion criteria and 228 patients declined to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-ERCP Group</title>
          <description>Pre-ERCP rectal Indomethacin in all patients.
Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
        </group>
        <group group_id="P2">
          <title>Post-ERCP Group</title>
          <description>Post-ERCP rectal Indomethacin in high-risk patients.
Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just in high-risk patients, while average risk patients did not.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1297"/>
                <participants group_id="P2" count="1303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1297"/>
                <participants group_id="P2" count="1303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-ERCP Group</title>
          <description>Pre-ERCP rectal Indomethacin in all patients.
Pre-operational rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
        </group>
        <group group_id="B2">
          <title>Post-ERCP Group</title>
          <description>Post-ERCP rectal Indomethacin in high-risk patients.
Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just in high-risk patients, while average risk patients did not.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1297"/>
            <count group_id="B2" value="1303"/>
            <count group_id="B3" value="2600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="50" upper_limit="72"/>
                    <measurement group_id="B2" value="63" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="B3" value="62" lower_limit="50" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="688"/>
                    <measurement group_id="B2" value="693"/>
                    <measurement group_id="B3" value="1381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="609"/>
                    <measurement group_id="B2" value="610"/>
                    <measurement group_id="B3" value="1219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-risk patients</title>
          <description>met at least one of the major criteria - clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, pneumatic dilatation of an intact biliary sphincter, or ampullectomy.
or met two or more of the minor criteria - age&lt;50 and female gender, a history of recurrent pancreatitis (≥2 episodes), ≥3 injections of contrast into the pancreatic duct with ≥1 injection to the tail of the pancreas, opacification of pancreatic acini, or brush cytology performed on the pancreatic duct.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-ERCP Pancreatitis</title>
        <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, serum amylase elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization prolonged at least two nights.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-ERCP Group</title>
            <description>Pre-ERCP rectal Indomethacin in all patients.
Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
          </group>
          <group group_id="O2">
            <title>Post-ERCP Group</title>
            <description>Post-ERCP rectal Indomethacin in high-risk patients.
Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just in high-risk patients, while average risk patients did not.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-ERCP Pancreatitis</title>
          <description>Subjects were diagnosed with post-ERCP pancreatitis if they experienced new upper abdominal pain, serum amylase elevation at least three times the upper limit of normal 24 hours after the procedure, and hospitalization prolonged at least two nights.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1297"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moderate-to-severe Pancreatitis</title>
        <description>Moderate pancreatitis requiring hospitalization of 4-10 days. Severe pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-ERCP Group</title>
            <description>Pre-ERCP rectal Indomethacin in all patients.
Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
          </group>
          <group group_id="O2">
            <title>Post-ERCP Group</title>
            <description>Post-ERCP rectal Indomethacin for high-risk patients.
Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just for high-risk patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Moderate-to-severe Pancreatitis</title>
          <description>Moderate pancreatitis requiring hospitalization of 4-10 days. Severe pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1297"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Adverse events related to ERCP or indomethacin include bleeding, perforation, biliary infection, cardiovascular or renal adverse events and other adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-ERCP Group</title>
          <description>Pre-ERCP rectal Indomethacin in all patients.
Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients.</description>
        </group>
        <group group_id="E2">
          <title>Post-ERCP Group</title>
          <description>Post-ERCP rectal Indomethacin in high-risk patients.
Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just in high-risk patients, while average risk patients did not.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Bleeding</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1297"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Moderate to severe bleeding</sub_title>
                <description>Moderate to severe bleeding was defined as clinically significant bleeding with hemoglobin level drop ≥3g with the need for transfusion, angiographic intervention or surgery.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1297"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="Biliary infection">Moderate to severe biliary infection</sub_title>
                <description>Febrile or septic illness requiring &gt;3 d of hospital treatment or need endoscopic or percutaneous intervention.
Septic shock or surgery.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1297"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.01</frequency_threshold>
        <default_vocab>Mild bleeding</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1297"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild bleeding</sub_title>
                <description>Clinical evidence of bleeding (ie, not just endoscopic); Hb level drop &lt;3 g; no need for transfusion.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1297"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1303"/>
              </event>
              <event>
                <sub_title vocab="Mild perforation">Mild perforation</sub_title>
                <description>Possible, or only very slight leak of fluid or contrast dye; treatable by fluids and suction for ≤3d</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1303"/>
              </event>
              <event>
                <sub_title vocab="Incomplete bowel obs">Incomplete bowel obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="Miliary infection">Mild biliary infection</sub_title>
                <description>Mild biliary infection was defined as a temperature of more than 38°C for 24–48 h after the procedure, thought to have a biliary cause (colicky pain and cholestasis/jaundice) without evidence of other concomitant infections.</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1297"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="1303"/>
              </event>
              <event>
                <sub_title vocab="Pulmonary infection">Pulmonary infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1297"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Firstly, patients could not be blinded to the treatment assignment. Secondly, it remains unclear if patients with prior EST will benefit from rectal indomethacin. Thirdly, the findings need to be validated in different clinical settings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hui Luo</name_or_title>
      <organization>Xijing hospital of digestive diseases</organization>
      <phone>862984771536</phone>
      <email>fmmulh@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

